Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 3/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783522 | 1.00 | CYP2C19 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL28707976 | 1.00 | CYP2C19 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL4339652 | 1.00 | CYP2C19 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL4195634 | 0.85 | CYP2C19 (0.47) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL342584 | 0.82 | ALDH1A1 (0.52) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL30509738 | 0.82 | ALDH1A1 (0.52) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL9751547 | 0.82 | ALDH1A1 (0.52) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| Hydrochloric Acid SCHEMBL2455223 | 0.80 | ALDH1A1 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| Hydrochloric Acid SCHEMBL2475384 | 0.80 | ALDH1A1 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A | |
| SCHEMBL22710196 | 0.80 | ALDH1A1 (0.50) | CYP2C19CYP1A2ALDH1A1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022169891-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-08-11 | — | — | WO | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| CN-100436406-C | Process for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| CN-1898193-A | Method for producing optically active bisamidealcohol compound | SUMITOMO CHEMICAL CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| JP-2004067671-A | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-AMINO-2-(1-NAPHTHYL)ETHANOLS AND INTERMEDIATE FOR THE SAME | SUMITOMO CHEM CO LTD | 2004-03-04 | — | — | JP | disclosed |
| JP-2004067671-A | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-AMINO-2-(1-NAPHTHYL)ETHANOLS AND INTERMEDIATE FOR THE SAME | SUMITOMO CHEM CO LTD | 2004-03-04 | — | — | JP | disclosed |
| EP-0182279-B1 | PROCESS FOR THE OPTICAL RESOLUTION OF RACEMIC MIXTURES OF ALPHA-NAPHTYL-PROPIONIC ACIDS | ALFA WASSERMANN S.p.A. (IT) | 1990-02-28 | — | — | EP | disclosed |
| EP-0211721-B1 | PHENYLETHANOL AMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1989-10-04 | — | — | EP | disclosed |
| US-4661628-A | Process for the optical resolution of racemic mixtures of α-naphthyl-propionic acids | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1987-04-28 | — | — | US | disclosed |
| US-4622419-A | AMIDATION, ACID HYDROLYSIS | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1986-11-11 | — | — | US | disclosed |
| EP-0182279-A1 | Process for the optical resolution of racemic mixtures of alpha-naphtyl-propionic acids | ALFA WASSERMANN S.p.A. (IT) | 1986-05-28 | — | — | EP | disclosed |
| EP-0143371-A1 | Process for the optical resolution of racemic mixtures of alpha-naphthyl-propionic acids | Alfa Chemicals Italiana S.r.l. (IT) | 1985-06-05 | — | — | EP | disclosed |
| US-4045485-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC AND ANTIPRURITIC ACTIVITY | SYNTEX CORPORATION (US) | 1977-08-30 | — | — | US | disclosed |
| US-3960936-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, SKIN DISORDERS | SYNTEX CORPORATION (PM) | 1976-06-01 | — | — | US | disclosed |
| US-3947472-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-03-30 | — | — | US | disclosed |
| US-3935273-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | SARS1, ACE, PLPBP | CYP2C19 1293/4885CYP1A2 2534/4885ALDH1A1 2979/4885 |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | CYP2C19 1911/4885CYP1A2 791/4885ALDH1A1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.